US 11,866,405 B2
Substituted indazoles as IRAK4 inhibitors
Ina Terstiege, Gothenburg (SE); Stefan Schiesser, Göthenburg (SE); Yafeng Xue, Göthenburg (SE); Hui-Fang Chang, Göthenburg (SE); and Anna Ingrid Kristina Berggren, Göthenburg (SE)
Assigned to AstraZeneca AB, Sodertalje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Dec. 1, 2021, as Appl. No. 17/457,249.
Claims priority of provisional application 63/199,160, filed on Dec. 10, 2020.
Prior Publication US 2022/0185817 A1, Jun. 16, 2022
Int. Cl. A61K 31/416 (2006.01); C07D 231/56 (2006.01); C07D 487/04 (2006.01); A61P 11/06 (2006.01); A61P 37/06 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 11/06 (2018.01); A61P 37/06 (2018.01)] 17 Claims
 
1. A compound of Formula (A):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
R1 is

OG Complex Work Unit Chemistry
R2 is

OG Complex Work Unit Chemistry
R4 is H, CH3, or CH2CH3;
Y is C(O)N(CH3)2 or N(R5)C(O)R6;
Z is H;
R5 is H, C1-C6 alkyl, or C3-C6 cycloalkyl;
R6 is C1-C6 alkyl or C3-C6 cycloalkyl;
wherein the C1-C6 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, C(O)CH3, NH2, NHCH3, N(CH3)2, OH, and OC1-C3 alkyl; and
wherein the C3-C6 cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of F, Cl, C1-C3 alkyl, C(O)CH3, NH2, NHCH3, N(CH3)2, OH, and OC1-C3 alkyl;
X is NR8R9 or OR7;
R7 is CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, or C3-C6 cycloalkyl;
R8 is H or C1-C6 alkyl; and
R9 is H or C1-C6 alkyl.